ACRS
$3.92+0.18 (+4.95%)
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States.
Recent News
Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference
Aclaris Therapeutics (NASDAQ:ACRS) outlined multiple clinical and near-term development milestones across its large-molecule and small-molecule pipeline during a presentation at the Leerink Partners Global Healthcare Conference, with management emphasizing upcoming data readouts in atopic dermatitis
Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference
Executives from Aclaris Therapeutics (NASDAQ:ACRS) outlined the company’s clinical-stage pipeline and upcoming catalysts during a presentation at Oppenheimer’s Annual Healthcare Conference, emphasizing programs in inflammatory and immunological diseases spanning monoclonal antibodies, a bispecific a
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of -9.59% and -33.04%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Aclaris: Q4 Earnings Snapshot
The Wayne, Pennsylvania-based company said it had a loss of 16 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 15 cents per share.
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +5.39% and +30.48%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?